Table 1 Study characteristics.
Study | Year | Sample Size (n) | Female, no. (%) | Ischemic heart disease, no. (%) | Previous catheter ablation, no. (%) | Mean Age (years) | Mean LVEF (%) | Timing of SGB and inclusion criteria |
|---|---|---|---|---|---|---|---|---|
Batnyam et al.35 | 2024 | 15 | 2 (13.3) | 8 (53.3) | 10 (66.7) | 62.8 | 31.8 | Refractory to medical therapies |
Cardona et al.33 | 2024 | 15 | 10 (66.7) | 1 (6.7) | NA | 67.8 | NA | Refractory – Failure of at least one IV AAD |
Chouairi et al.32 | 2024 | 117 | 7 | 61 (52.1) | 66 (56.4) | 63.5 | 26.7 | Refractory to conventional therapies |
Dhanse et al.21 | 2022 | 11 | 7 (63.6) | 9 (81.8) | NA | 62.7 | 33.9 | Refractory – Failure of IV amiodarone, lidocaine and Mg |
Halawa et al.22 | 2021 | 19 | 2 (10.5) | 10 (52.6) | 9 (47.3) | 66.5 | 28 | NA |
Kotti et al.23 | 2019 | 11 | NA | 11 (100) | NA | 57 | 35 | Refractory – Failure of at least one oral and one IV AAD |
Lador et al.24 | 2023 | 25 | 6 (24) | 14 (56) | 12 (48.0) | 59.2 | 20 | Refractory – Not controlled by AADs |
Markman et al.25 | 2023 | 11 | 2 (18.2) | 6 (54.5) | 6 (54.5) | 59 | 15 | Refractory – NA |
Otakar et al.26 | 2023 | 59 | 3 (5.1) | 42 (71.2) | NA | 67.7 | 30 | Refractory – failure of immediate therapy, including sedation and AADs |
Pasula et al.27 | 2023 | 56 | 16 (28.6) | 43 (76.8) | NA | 60 | NA | Refractory – Failure of two AADs |
Patel et al.28 | 2023 | 11 | 1 (9.1) | 10 (90.9) | NA | 62.1 | NA | NA |
Reinertsen et al. 29 | 2021 | 13 | 3 (23.1) | 6 (46.2) | NA | 64 | 23 | Refractory – Drug refractory |
Sanghai et al.30 | 2021 | 18 | 2 (11.1) | 7 (38.9) | NA | 61.1 | 30.9 | Refractory – Failure of at least one AAD |
Savastano et al.34 | 2024 | 131 | 22 (16.8) | 37 (28.2) | NA | 68 | 25 | Refractory – Failure of at least one IV AAD |
Tian et al.31 | 2019 | 30 | 8 (26.7) | 17 (56.7) | 14 (46.7) | 58 | 34 | NA |
